目的 探討復(fù)方垂盆草膠囊聯(lián)合替富馬酸替諾福韋二吡呋酯片治療慢性乙型病毒性肝炎的臨床療效。方法 選取2016年9月-2017年9月在儋州市人民醫(yī)院治療的慢性乙型病毒性肝炎患者96例，隨機(jī)分為對(duì)照組（48例）和治療組（48例）。對(duì)照組口服富馬酸替諾福韋二吡呋酯片，300 mg/次，1次/d；治療組在對(duì)照組基礎(chǔ)上口服復(fù)方垂盆草膠囊，4粒/次，3次/d。兩組均治療12周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者肝功能、肝纖維化指標(biāo)、體液免疫指標(biāo)、T淋巴細(xì)胞亞群水平。結(jié)果 治療后，對(duì)照組臨床有效率為81.25%，顯著低于治療組的97.92%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者丙氨酸轉(zhuǎn)氨酶（ALT）、門冬氨酸轉(zhuǎn)氨酶（AST）、總膽紅素（TBIL）水平均顯著降低（P<0.05），且治療組患者肝功能指標(biāo)水平明顯低于對(duì)照組（P<0.05）。治療后，兩組患者透明質(zhì)酸（HA）、層粘連蛋白（LN）、Ⅲ型前膠原肽（PC-Ⅲ）、Ⅳ膠原蛋白（Ⅳ-C）水平均顯著降低（P<0.05），且治療組患者上述肝纖維化指標(biāo)明顯低于對(duì)照組（P<0.05）。治療后，兩組患者IL-2和IL-21水平均顯著升高（P<0.05），IL-17和IL-22水平顯著降低（P<0.05），且治療組這些體液免疫指標(biāo)治療后水平明顯優(yōu)于對(duì)照組（P<0.05）。治療后，兩組CD3⁺、CD4⁺、CD4⁺/CD8⁺水平均顯著增高（P<0.05），且CD8⁺水平顯著降低（P<0.05），同時(shí)治療后治療組T淋巴細(xì)胞亞群水平明顯優(yōu)于對(duì)照組（P<0.05）。結(jié)論 復(fù)方垂盆草膠囊聯(lián)合替富馬酸替諾福韋二吡呋酯治療慢性乙型病毒性肝炎可有效改善患者肝功能，提高機(jī)體免疫力，預(yù)防肝纖維化，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the clinical efficacy of Compound Chuipencao Capsules combined with tenofovir disoproxil in treatment of chronic hepatitis B. Methods Patients (96 cases) with chronic hepatitis B in Danzhou People's Hospital from September 2016 to September 2017 were randomly divided into control (48 cases) and treatment (48 cases) groups. Patients in the control group were po administered with Tenofovir Disoproxil Fumarate Tablets, 300 mg/time, once daily. Patients in the treatment group were po administered with Compound Chuipencao Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, the liver function, the liver fibrosis indexes, humoral immune indexes, and level of T lymphocyte subsets in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.25%, which was significantly lower than 97.92% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the ALT, AST and TBIL levels in two groups were significantly decreased (P<0.05), and these liver function indexes levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the HA, LN, PC-Ⅲ, and Ⅳ-C levels in two groups were significantly decreased (P<0.05), and these liver fibrosis indexes levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the IL-2 and IL-21 levels in two groups were significantly increased (P<0.05), but IL-17 and IL-22 levels were significantly decreased (P<0.05), and the humoral immune indexes in the treatment group after treatment were significantly better than those in the control group (P<0.05). After treatment, the CD3⁺, CD4⁺ and CD4⁺/CD8⁺ levels in two groups were significantly increased (P<0.05), but CD8⁺ levels were significantly decreased (P<0.05), and the level of T lymphocyte subsets in the treatment group after treatment was significantly better than those in the control group (P<0.05). Conclusion Compound Chuipencao Capsules combined with tenofovir disoproxil in treatment of chronic hepatitis B can improve liver function, immunity and prevent liver fibrosis, which has a certain clinical application value.